The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes

Syed MR Gillani, Baldev M Singh

Abstract


Introduction: In obesity, bariatric surgery is effective but carries morbidity and mortality risks. In type 2 diabetes, glucagon-like peptide-1 (GLP-1) agonist therapy results in weight reduction. Randomised controlled trials show efficacy in the non-diabetes obese population. Thus we have audited GLP-1 agonist use for weight reduction in morbidly obese people without diabetes.

Methods: A protocol for GLP-1 use in non-diabetes obesity (body mass index >35 kg/m2) was agreed with local clinical governance committees. After liraglutide initiation, follow up was monthly, and the dose was up-titrated to a maximal 3 mg daily if indicated.

Results: Of 34 people offered treatment, 22 proceeded (age 42 ± 14 years, 17 females, 16 White Caucasians) and 14 completed 12 months of treatment. Absolute weight fell significantly from a baseline of 127 ± 19 kg (n=22) to 121 ± 19 kg (n=22), 119 ± 21 kg (n=21) and 110 ± 15 kg (n=14) kg at 3, 6 and 12 months respectively (all p<0.001 from baseline) amounting to -5.3 ± 4.4 kg, -7.4 ± 7.7 kg and -12.1± 9.6 kg at 3, 6 and 12 months respectively (all p<0.001 from baseline).

Conclusions: GLP-1 agonist therapy may play a significant role in people who have failed other weight loss options and are potential candidates for bariatric surgery.

Full Text:

HTML PDF

References


Deitel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg 2003;13:329-30. http://dx.doi.org/10.1381/096089203765887598

Statistics on Obesity, Physical Activity and Diet: England 2014; available at: http://www.hscic.gov.uk/catalogue/PUB13648/Obes-phys-acti-diet-eng-2014-rep.pdf

Waterland RA, Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999;69(2):179-97.

Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial. JAMA 2005; 293:43-53. http://dx.doi.org/10.1001/jama.293.1.43

Brinkworth GD, Wycherley TP, Noakes M, Clifton PM. Reductions in blood pressure following energy restriction for weight loss do not rebound after re-establishment of energy balance in overweight and obese subjects. Clin Exp Hypertens 2008;30:385-96. http://dx.doi.org/10.1080/10641960802275734

Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353:2111-20. http://dx.doi.org/10.1056/NEJMoa050156

Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102-07. http://dx.doi.org/10.2337/dc06-0560

North American Association for the Study of Obesity and the National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md: National Institutes of Health; 2000. NIH publication 00-4084

Brolin RE. Bariatric surgery and long-term control of morbid obesity; JAMA 2002;288(22):2793-6. http://dx.doi.org/10.1001/jama.288.22.2793

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292(14):1724-37. http://dx.doi.org/10.1001/jama.292.14.1724

Buchwald H. A bariatric surgery algorithm. Obes Surg 2002;12:733-46. http://dx.doi.org/10.1381/096089202320995484

Hermann C, Goke R, Richter G, Fehmann H, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117-26. http://dx.doi.org/10.1159/000201231

Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and [beta]-cell function in type 2 diabetes: A parallel-group study. Lancet 2002;359:824-30. http://dx.doi.org/10.1016/S0140-6736(02)07952-7

Garber A J. Long-acting glucagon-like peptide 1 receptor agonists; a review of their efficacy and tolerability. Diabetes Care 2011;34(Supplement 2):S279-S284. http://dx.doi.org/10.2337/dc11-s231

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771. http://dx.doi.org/10.1136/bmj.d7771

Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57. http://dx.doi.org/10.1053/j.gastro.2007.03.054

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4. pmid:8405741

Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16. http://dx.doi.org/10.1016/S0140-6736(09)61375-1

Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-5. http://dx.doi.org/10.2337/dc09-1203

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes 2013;37:1443-51. http://dx.doi.org/10.1038/ijo.2013.120

Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f5934. http://dx.doi.org/10.1136/bmj.f5934

Maggard M, Shugarman L, Suttorp M, et al: Meta-analysis: surgical treatment for obesity. Ann Intern Med 2005;142:547-59. http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00013

Puzziferri N, Austrheim IT, Wolfe BM, Wilson SE, Hguyen NT. Three-year follow-up of a prospective randomized trial comparing laparoscopic versus open gastric bypass. Ann Surg 2006;243:181-8. http://dx.doi.org/10.1097/01.sla.0000197381.01214.76

Favretti F, Segato G, Ashton D, et al. Laparoscopic adjustable gastric banding in 1,791 consecutive obese patients: 12-year results. Obes Surg 2007;17:168-75. http://dx.doi.org/10.1007/s11695-007-9043-0

Goodney PP, Siewers AE, Stukel TA, et al. Is surgery getting safer? National trends in operative mortality. J Am Coll Surg 2002;195:219-27. http://dx.doi.org/10.1016/S1072-7515(02)01228-0

Flum DR, Salem L, Elrod JA, Dellinger LP, Cheadle A, Chan L. Early mortality among medicare beneficiaries undergoing bariatric surgical procedures. JAMA 2005;294:1903-08. http://dx.doi.org/10.1001/jama.294.15.1903

Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide. Int J Obes (Lond) 2012;36(6):843-54. http://dx.doi.org/10.1038/ijo.2011.158




DOI: https://doi.org/10.15277/bjdvd.2015.011

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists